India bears a disproportionate share of the global diabetes burden, with 89.8 million adults living with T2DM against a ...

Wearable bands are increasingly optimized for continuous health monitoring, with some vendors exploring screenless or reduced-screen designs to improve comfort and data continuity. “The wearables ...

Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension (RH). Agents such as baxdrostat, the first selective aldosterone ...

The ACC and AHA released updated guidelines for the management of dyslipidemia to reduce risk for atherosclerotic cardiovascular disease.

New hypertension treatments may reduce dosage to two injections annually instead of daily pills Zilebesiran uses siRNA to lower blood pressure by targeting angiotensinogen production in the liver Long ...

Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

Introduction Hypertension programmes have expanded substantially in low-income and middle-income countries, yet treatment and control rates remain insufficient. Programme scale-up may lead to ...

NHS patients with type 2 diabetes (T2D) in England will get earlier access to SGLT-2 inhibitors, now that generics of one of the main drugs in the class – AstraZeneca's Forxiga – are available. Final ...

WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ — Even with the advancement of Automated Insulin Delivery (AID) technologies, diabetes management ...

Earnings call Esperion posted its strongest quarter ever, with Q4 revenue up 144% YoY and U.S. net product sales rising 38%. The planned Corstasis acquisition, strong cash position, and imminent U.S.

Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today's conference call will be recorded. I would now like to hand the conference over to ...